Protagenic Therapeutics (PTIX) - Net Assets
Based on the latest financial reports, Protagenic Therapeutics (PTIX) has net assets worth $-4.69 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.13 Million) and total liabilities ($6.82 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Protagenic Therapeutics's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-4.69 Million |
| % of Total Assets | -220.06% |
| Annual Growth Rate | N/A |
| 5-Year Change | -147.19% |
| 10-Year Change | -289.41% |
| Growth Volatility | 319.83 |
Protagenic Therapeutics - Net Assets Trend (1995–2025)
This chart illustrates how Protagenic Therapeutics's net assets have evolved over time, based on quarterly financial data. Also explore Protagenic Therapeutics (PTIX) total assets for the complete picture of this company's asset base.
Annual Net Assets for Protagenic Therapeutics (1995–2025)
The table below shows the annual net assets of Protagenic Therapeutics from 1995 to 2025. For live valuation and market cap data, see PTIX market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-4.69 Million | -563.08% |
| 2024-12-31 | $1.01 Million | -72.38% |
| 2023-12-31 | $3.67 Million | -46.97% |
| 2022-12-31 | $6.92 Million | -30.42% |
| 2021-12-31 | $9.94 Million | +964.72% |
| 2020-12-31 | $-1.15 Million | -81.24% |
| 2019-12-31 | $-634.37K | -200.81% |
| 2018-12-31 | $-210.88K | -117.30% |
| 2017-12-31 | $1.22 Million | -50.78% |
| 2016-12-31 | $2.48 Million | +533.81% |
| 2015-12-31 | $-571.00K | -14.89% |
| 2015-06-30 | $-497.00K | -610.00% |
| 2014-12-31 | $-70.00K | 0.00% |
| 2013-12-31 | $-70.00K | +99.59% |
| 2012-12-31 | $-17.23 Million | -310.79% |
| 2010-12-31 | $8.17 Million | -67.76% |
| 2009-12-31 | $25.35 Million | -53.62% |
| 2008-12-31 | $54.65 Million | +224.04% |
| 2007-12-31 | $16.86 Million | +1278.99% |
| 2006-12-31 | $1.22 Million | -55.33% |
| 2004-12-31 | $2.74 Million | -45.02% |
| 2003-12-31 | $4.98 Million | -61.32% |
| 2002-12-31 | $12.87 Million | -5.10% |
| 2001-12-31 | $13.57 Million | -2.11% |
| 2000-12-31 | $13.86 Million | +4.41% |
| 1999-12-31 | $13.27 Million | -4.83% |
| 1998-12-31 | $13.95 Million | +4.87% |
| 1997-12-31 | $13.30 Million | +88.91% |
| 1996-12-31 | $7.04 Million | -6.26% |
| 1995-12-31 | $7.51 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Protagenic Therapeutics's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 708385600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $195.00 | % |
| Other Comprehensive Income | $-220.01K | % |
| Other Components | $6.94 Million | % |
| Total Equity | $-2.39 Million | 100.00% |
Protagenic Therapeutics Competitors by Market Cap
The table below lists competitors of Protagenic Therapeutics ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shield Therapeutics plc
LSE:STX
|
$1.03 Million |
|
Thiensurat Public Company Limited
BK:TSR
|
$1.03 Million |
|
Boxlight Corp Class A
NASDAQ:BOXL
|
$1.03 Million |
|
Biophytis S.A.
PA:ALBPS
|
$1.03 Million |
|
BEACN Wizardry & Magic Inc
V:BECN
|
$1.02 Million |
|
Total Helium Ltd
V:TOH
|
$1.02 Million |
|
AfriTin Mining Ltd
LSE:ATM
|
$1.02 Million |
|
Edri-El
TA:EDRL
|
$1.02 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Protagenic Therapeutics's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,013,154 to -2,392,688, a change of -3,405,842 (-336.2%).
- Net loss of 5,156,250 reduced equity.
- Other comprehensive income decreased equity by 90,156.
- Other factors increased equity by 1,840,564.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-5.16 Million | -215.5% |
| Other Comprehensive Income | $-90.16K | -3.77% |
| Other Changes | $1.84 Million | +76.92% |
| Total Change | $- | -336.16% |
Book Value vs Market Value Analysis
This analysis compares Protagenic Therapeutics's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1995-12-31 | $1.77 | $0.80 | x |
| 1996-12-31 | $1.66 | $0.80 | x |
| 1997-12-31 | $13299000.00 | $0.80 | x |
| 1998-12-31 | $13947000.00 | $0.80 | x |
| 1999-12-31 | $13273000.00 | $0.80 | x |
| 2000-12-31 | $13859000.00 | $0.80 | x |
| 2001-12-31 | $13566000.00 | $0.80 | x |
| 2002-12-31 | $12874000.00 | $0.80 | x |
| 2003-12-31 | $1.17 | $0.80 | x |
| 2004-12-31 | $0.65 | $0.80 | x |
| 2005-12-31 | $-9447000.00 | $0.80 | x |
| 2006-12-31 | $1223000.00 | $0.80 | x |
| 2007-12-31 | $338408.16 | $0.80 | x |
| 2008-12-31 | $632430.23 | $0.80 | x |
| 2009-12-31 | $301750.00 | $0.80 | x |
| 2010-12-31 | $80117.65 | $0.80 | x |
| 2012-12-31 | $-0.01 | $0.80 | x |
| 2013-12-31 | $-2.69 | $0.80 | x |
| 2014-12-31 | $-3.23 | $0.80 | x |
| 2015-12-31 | $-4.21 | $0.80 | x |
| 2016-12-31 | $1.87 | $0.80 | x |
| 2017-12-31 | $0.48 | $0.80 | x |
| 2018-12-31 | $-0.08 | $0.80 | x |
| 2019-12-31 | $-0.25 | $0.80 | x |
| 2020-12-31 | $-0.44 | $0.80 | x |
| 2021-12-31 | $2.70 | $0.80 | x |
| 2022-12-31 | $1.60 | $0.80 | x |
| 2023-12-31 | $0.84 | $0.80 | x |
| 2024-12-31 | $0.21 | $0.80 | x |
| 2025-12-31 | $-1.24 | $0.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Protagenic Therapeutics utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-59.75%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1995 | -8.00% | -8.70% | 0.62x | 1.48x | $-1.35 Million |
| 1996 | -4.26% | -3.03% | 0.79x | 1.79x | $-1.00 Million |
| 1997 | -6.77% | -7.16% | 0.80x | 1.19x | $-2.23 Million |
| 1998 | 4.65% | 4.15% | 0.73x | 1.54x | $-746.70K |
| 1999 | -5.08% | -3.59% | 0.82x | 1.73x | $-2.00 Million |
| 2000 | 8.20% | 5.31% | 0.93x | 1.65x | $-249.90K |
| 2001 | 1.06% | 0.67% | 0.93x | 1.72x | $-1.21 Million |
| 2002 | -5.65% | -3.92% | 0.86x | 1.67x | $-2.02 Million |
| 2003 | -158.95% | 0.00% | 0.00x | 2.76x | $-8.40 Million |
| 2004 | -81.59% | 0.00% | 0.00x | 2.54x | $-2.51 Million |
| 2005 | 0.00% | 0.00% | 0.00x | 0.00x | $-85.02K |
| 2006 | 55.36% | 3.62% | 3.41x | 4.49x | $554.70K |
| 2007 | -25.02% | -11.22% | 1.54x | 1.45x | $-5.81 Million |
| 2008 | -212.85% | -101.65% | 1.45x | 1.45x | $-121.20 Million |
| 2009 | -116.27% | -42.66% | 1.55x | 1.76x | $-32.00 Million |
| 2010 | -241.40% | -49.29% | 2.07x | 2.37x | $-20.54 Million |
| 2012 | 0.00% | -1208.24% | 0.09x | 0.00x | $695.60K |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.07 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.08 Million |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-426.30K |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-426.30K |
| 2016 | -91.88% | 0.00% | 0.00x | 1.28x | $-2.52 Million |
| 2017 | -185.35% | 0.00% | 0.00x | 1.46x | $-2.38 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.54 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.69 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.43 Million |
| 2021 | -45.49% | 0.00% | 0.00x | 1.11x | $-5.52 Million |
| 2022 | -51.41% | 0.00% | 0.00x | 1.16x | $-4.25 Million |
| 2023 | -136.31% | 0.00% | 0.00x | 1.18x | $-5.37 Million |
| 2024 | -545.33% | 0.00% | 0.00x | 1.93x | $-5.63 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.92 Million |
Industry Comparison
This section compares Protagenic Therapeutics's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Protagenic Therapeutics (PTIX) | $-4.69 Million | -8.00% | N/A | $1.03 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Protagenic Therapeutics
Protagenic Therapeutics, Inc. operates as a pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules. Protagenic Therapeutics, Inc. was founded in 2004 and is based in Santa Barbara, California.